These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37209178)

  • 1. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism.
    Liu YN; Chen J; Wang J; Li Q; Hu GX; Cai JP; Lin G; Xu RA
    Arch Toxicol; 2023 Aug; 97(8):2133-2142. PubMed ID: 37209178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone.
    Li Q; Wang J; Wang ZL; Shen Y; Zhou Q; Liu YN; Hu GX; Cai JP; Xu RA
    Biomed Pharmacother; 2023 Dec; 168():115833. PubMed ID: 37935069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism.
    Ye Z; Hu J; Wang J; Liu YN; Hu GX; Xu RA
    Chem Biol Interact; 2023 Apr; 374():110398. PubMed ID: 36773832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS.
    Lin QM; Pang NH; Li YH; Huang HL; Zhang XD; Hu GX; Wang ZS
    Chem Biol Interact; 2019 Sep; 310():108744. PubMed ID: 31299239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline.
    Hu X; Ni J; Gao N; Ye Z; Hu G; Cai J; Qian J
    Chem Biol Interact; 2022 Oct; 366():110123. PubMed ID: 36007633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Polymorphisms and Drug-Drug Interactions Determine the Metabolic Profile of Blonanserin.
    Ye F; Li X; Ni J; Xu X; Luo J; Zhong Y; Wang Y; Wang S; Zhang Y; Hu G; Qian J
    J Pharmacol Exp Ther; 2024 Jan; 388(1):190-200. PubMed ID: 37863485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the antitumor drugs adagrasib and asciminib on apixaban metabolism in vitro and in vivo.
    Shen Y; Chen X; Wu H; Xia H; Xu RA
    Chem Biol Interact; 2024 Aug; 399():111146. PubMed ID: 39002878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.
    Zhao K; Ding M; Cao H; Cao ZX
    J Pharm Pharmacol; 2012 Oct; 64(10):1445-51. PubMed ID: 22943175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A4 and CYP2C19 genetic polymorphisms and myricetin interaction on tofacitinib metabolism.
    Ye Z; Xia H; Hu J; Liu YN; Wang A; Cai JP; Hu GX; Xu RA
    Biomed Pharmacother; 2024 Jun; 175():116421. PubMed ID: 38719708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The variability in CYP3A4 activity determines the metabolic kinetic characteristics of ketamine.
    Li M; Li Q; Lin D; Zheng X; Jin L; Cai J; Hu G; Qian J
    Toxicology; 2023 Dec; 500():153682. PubMed ID: 38006927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of myricetin and quercetin on ticagrelor metabolism and the underlying mechanism.
    Wang J; Hu Y; Li Q; Liu YN; Lin J; Xu RA
    Chem Biol Interact; 2024 Apr; 392():110924. PubMed ID: 38401715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of shikonin on the metabolism of lapatinib in vitro, and in vivo.
    Hu Y; Xie S; Xia H; Chen J; Yang Y; Zhan R
    Toxicol Appl Pharmacol; 2024 Jan; 482():116797. PubMed ID: 38160892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism.
    Gao N; Zhang X; Hu X; Kong Q; Cai J; Hu G; Qian J
    Front Pharmacol; 2022; 13():794931. PubMed ID: 35359868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of UPLC-MS/MS method for studying the pharmacokinetic interactions of fuzuloparib with curcumin in rats.
    Wu H; Xie S; Chen X; Xia H; Shen Y; Xu RA; Tan W; Zhan R
    J Pharm Biomed Anal; 2024 Oct; 249():116383. PubMed ID: 39096626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism.
    Zhou Q; Ye F; Ye Z; Gao N; Kong Q; Hu X; Qian J; Wu B
    PeerJ; 2023; 11():e16601. PubMed ID: 38089912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of napabucasin on arbidol metabolism and its mechanism research.
    Nie J; Xia H; Liu YN; Yu Y; Xu RA
    Front Pharmacol; 2023; 14():1292354. PubMed ID: 38094891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of CYP3A4 genetic polymorphism on crizotinib metabolism and drug-drug interactions.
    Wang J; Xu XY; Li XY; Luo JC; Zhang ZY; Chen J; Cai JP; Zhang LK; Qian JC
    Toxicol Appl Pharmacol; 2024 Aug; 489():117016. PubMed ID: 38925514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic interactions of magnolol with cytochrome P450 enzymes: uncompetitive inhibition of CYP1A and competitive inhibition of CYP2C.
    Kim SB; Kang HE; Cho HJ; Kim YS; Chung SJ; Yoon IS; Kim DD
    Drug Dev Ind Pharm; 2016; 42(2):263-9. PubMed ID: 26133083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol.
    Usmani KA; Hodgson E; Rose RL
    Chem Biol Interact; 2004 Dec; 150(3):221-32. PubMed ID: 15560889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of resveratrol on the pharmacokinetic of ibrutinib by UPLC-MS/MS.
    Wen J; Bao SS; Zhang BW; Liu TH; Ou-Yang QG; Cai JP; Zhou HY
    Drug Dev Ind Pharm; 2019 Jan; 45(1):27-31. PubMed ID: 30156133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.